Critical Evaluation of the Use of Cell Cultures for Inclusion in Clinical Trials of Patients Affected by Collagen VI Myopathies

P. SABATELLI,1 E. PALMA,2 A. ANGELIN,2 S. SQUARZONI,1 A. URCIUOLO,3 C. PELLEGRINI,4 T. TIEPOLO,3 P. BONALDO,3 F. GUALANDI,4 L. MERLINI,4,5 P. BERNARDI,2 AND N.M. MARALDI5,6*

1CNR—National Research Council of Italy, Institute of Molecular Genetics c/o IOR, Bologna, Italy
2Department of Biomedical Sciences, CNR Institute of Neuroscience, University of Padova, Padova, Italy
3Department of Histology, Microbiology and Medical Biotechnology, University of Padova, Padova, Italy
4Department of Experimental and Diagnostic Medicine, University of Ferrara, Ferrara, Italy
5Laboratory of Musculoskeletal Cell Biology, Istituto Ortopedico Rizzoli, Bologna, Italy
6Department of Anatomical Science, University of Bologna, Bologna, Italy

Collagen VI myopathies (Ullrich congenital muscular dystrophy (UCMD), Bethlem myopathy (BM), and myosclerosis myopathy) share a common pathogenesis, that is, mitochondrial dysfunction due to deregulation of the permeability transition pore (PTP). This effect was first identified in the Col6a1−/− mouse model and then in muscle cell cultures from UCMD and BM patients; the normalizing effect of cyclosporin A (CsA) confirmed the pathogenic role of PTP opening. In order to determine whether mitochondrial performance can be used as a criterion for inclusion in clinical trials and as an outcome measure of the patient response to therapy, it is mandatory to establish whether mitochondrial dysfunction is conserved in primary cell cultures from UCMD and BM patients. In this study we report evidence that mitochondrial dysfunction and the consequent increase of apoptotic rate can be detected not only, as previously reported, in muscle, but also in fibroblast cell cultures established from muscle biopsies of collagen VI-related myopathic patients. However, the mitochondrial phenotype is no longer maintained after nine passages in culture. These data demonstrate that the dire consequences of mitochondrial dysfunction are not limited to myogenic cells, and that this parameter can be used as a suitable diagnostic criterion, provided that the cell culture conditions are carefully established.

J. Cell. Physiol. 227: 2927–2935, 2012. © 2011 Wiley Periodicals, Inc.

The extracellular matrix (ECM) plays a critical role in maintaining muscle function and integrity, and defects of its constituent proteins such as laminin-2 and collagen (Col) VI are involved in the molecular pathogenesis of various forms of muscular dystrophy (Schessl et al., 2006). ColVI is a major ECM protein forming a distinct microfilamentous network in several organs including skeletal muscle (Keene et al., 1988). In this tissue ColVI is a major component of the endomysium, where it is localized just outside the basement membrane (Kuo et al., 1997). ColVI controls survival and proliferation of normal and transformed cells, and increased levels of ColVI are associated with tumorigenesis and resistance to chemotherapeutic drugs (Iyengar et al., 2003; Sherman-Baust et al., 2003).

Deficiency of ColVI in humans due to mutations of COL6 genes gives rise to three main muscle disorders: Bethlem myopathy (BM, MIM #158810), Ullrich congenital muscular dystrophy (UCMD, MIM #254090) (Lampe and Bushby, 2005), and myosclerosis myopathy (MIM #255600) (Merlini et al., 2008b).

BM is characterized by axial and proximal muscle weakness (Bethlem and Wijngaard, 1976), and the hallmark of the disease is the presence of contractures of the interphalangeal joints of the last four fingers (Merlini et al., 1994). BM is a very heterogeneous disorder and patients show a wide range of clinical features, from mild myopathy to more severe cases with early onset and features of progressive muscular dystrophy (Jobis et al., 1999). Immunohistochemistry shows apparently normal or mildly reduced levels of ColVI in the endomysium of most BM patients.

UCMD is a severe congenital muscular dystrophy characterized by early onset, generalized and rapidly progressive muscle wasting and weakness, proximal joint contractures, and distal joint hyperflexibility. Walking ability is rarely achieved or preserved in UCMD patients, and the rapid progression of the clinical symptoms usually leads to early death, due to respiratory failure (Camacho Vanegas et al., 2001; Demir et al., 2002). ColVI is usually strongly reduced or

*Correspondence to: N.M. Maraldi, Laboratory of Musculoskeletal Cell Biology, Istituto Ortopedico Rizzoli, via di Barbiano 1/10, Bologna, Italy. E-mail: maraldi@area.bo.cnr.it

Received 12 August 2011; Accepted 16 September 2011
Published online in Wiley Online Library (wileyonlinelibrary.com), 27 September 2011.

DOI: 10.1002/jcp.23039
absent in the muscle endomysium of UCMD patients. Cultured skin fibroblasts of UCMD patients show either a markedly decreased secretion of ColVI or lack of the characteristic filamentous network in the ECM, suggesting that UCMD mutations severely affect the synthesis and secretion of ColVI (Camacho Vanegas et al., 2001; Zhang et al., 2002; Squarzoni et al., 2006).

Myosclerosis Myopathy is characterized by progressive contractures of all joints, including jaws, spine, shoulders, elbows, wrists, fingers, hips, and knees. Patients are affected by scoliosis, mild girdle and proximal limb weakness, and moderate distal weakness. Muscles become thin and sclerotic and reach a woody consistency, causing diffuse restriction of movement of all joints, with marked difficulty in running and climbing stairs (Merlini et al., 2008b).

About 70 different mutations of the COL6 genes have so far been associated either with UCMD or with BM (Lampe and Bushby, 2005); and although the reason why certain COL6 mutations cause BM and others cause UCMD remains obscure, it appears that these disorders represent a clinical continuum rather than strictly separate entities (Pepe et al., 2002; Lampe and Bushby, 2005).

On the other hand, ColVI myopathies appear to share a common pathogenesis, that is, mitochondrial dysfunction due to deregulation of the permeability transition pore (PTP), an inner membrane high conductance channel (Bernardi et al., 2003). First identified in the Col6a1<sup>−/−</sup> mouse model (Irwin et al., 2003), the mitochondrial defect has been detected in cultures from UCMD and BM patients (Angelin et al., 2007; Angelin et al., 2008), findings that led to a promising pilot trial with the PTP inhibitor cyclosporin A (CsA) (Merlini et al., 2008b). The normalizing effect of CsA (Irwin et al., 2003), of its non-immunosuppressive derivative Debo 025 (Tiepolo et al., 2009), as well as of genetic inactivation of the Ppif gene encoding cyclophilin (CyP) D (the mitochondrial receptor for CsA) in the Col6a1<sup>−/−</sup> mouse (Palma et al., 2009) confirmed the pathogenic role of PTP opening, whose consequences are amplified by defective autophagy of the abnormal mitochondria (Grumati et al., 2010).

A typical feature of primary muscle-derived cultures from Col6a1<sup>−/−</sup> mice, UCMD, and BM patients is abnormal depolarization induced by the F1FO ATP synthase inhibitor oligomycin (Klöhn et al., 2003; Angelin et al., 2007; Angelin et al., 2008; Merlini et al., 2008a), a phenotype that is normalized by treatment with CyP inhibitors, plating on ColVI, CyPD ablation, or stimulation of autophagy (Irwin et al., 2003; Angelin et al., 2007; Merlini et al., 2008a; Tiepolo et al., 2009; Palma et al., 2009; Grumati et al., 2010).

In this study we report evidence that mitochondrial dysfunction and the consequent increase of apoptotic rate occurs in cell cultures derived from muscle biopsies of UCMD and BM patients, many of which were not included in our previous studies. We provide evidence that the mitochondrial dysfunction occurs not only, as previously reported, in muscle, but also in fibroblast cell cultures established from muscle biopsies of these patients. Furthermore, the reported data indicate that the mitochondrial phenotype is no longer maintained after nine passages in culture. These data demonstrate that the dire consequences of mitochondrial dysfunction are not limited to myogenic cells, and that this parameter can be used as a suitable diagnostic criterion for inclusion in clinical trials and for evaluating the response to therapy, provided that the cell culture conditions are carefully established.

### Materials and Methods

#### Patients

BM and UCMD were diagnosed according to the criteria of the European Neuromuscular Center (Pepe et al., 2002). All patients were examined and all underwent a muscle biopsy. The basic features of the patients analyzed in this study are summarized in Table 1. All participants provided written informed consent, and approval was obtained from the Ethics Committee of the Rizzoli Orthopedic Institute (Bologna, Italy).

#### Primary muscle-derived cell cultures

We obtained muscle biopsies from healthy donors, BM, and UCMD patients. Cell cultures were established using enzymatic and mechanical treatment and plating in Dulbecco’s modified Eagle’s medium (DMEM) plus 20% fetal calf serum (FCS) and antibiotics (penicillin, streptomycin, and amphotericin B; Sigma, St. Louis, MO) and then stored in liquid nitrogen.

#### Immunofluorescence on cell cultures

Muscle-derived cell cultures were fixed with cold methanol, washed with PBS, and incubated with desmin antibody (Abcam, Cambridge, UK). The immunoreaction was revealed with TRITC-conjugated antibody (DAKO, Atlanta, GA) and the samples were mounted with Pro-long anti-fade reagent (Molecular Probes, Eugene, OR) and examined with Nikon epifluorescence microscope at ×100 magnification.

#### Measurements of mitochondrial membrane potential

Mitochondrial membrane potential was measured by epifluorescence microscopy based on the accumulation of tetramethylrhodamine methyl ester (TMRM) as described previously (Angelin et al., 2007). Muscle-derived cell cultures (30,000–35,000 cells) were seeded onto 24 mm-diameter round glass coverslips, grown for 2 days in DMEM supplemented with 20% FCS and studied as described after loading with 10 nM TMRM in 1 ml of serum-free DMEM.

#### Transmission electron microscopy

Muscle-derived cells were grown in DMEM supplemented with 20% FCS until confluence, fixed with 2.5% glutaraldehyde in cacodylate buffer 0.1 M, pH 7.2, and post-fixed with 1% osmium tetroxide in cacodylate buffer 0.1 M, pH 7.3. After detaching with propylene oxide, the cells were centrifuged and embedded in Epon (30,000–35,000 cells) were infiltrated and maintained after nine passages in culture. These data demonstrate that the dire consequences of mitochondrial dysfunction are not limited to myogenic cells, and that this parameter can be used as a suitable diagnostic criterion for inclusion in clinical trials and for evaluating the response to therapy, provided that the cell culture conditions are carefully established.

### Table 1. Features of patients involved in the study

| Patient no. | Phenotype | Age (year) | Collagen VI | Mutation |
|-------------|-----------|------------|-------------|----------|
| 1           | BM, walker| 31         | Normal in skin, cultured fibroblasts, and skeletal muscle | COL6A3: heterozygous Gly7077Asp |
| 2           | BM, walker| 57         | Normal in muscle fibers and decreased in fibroblasts | COL6A1: heterozygous Tyr122–Gly143del |
| 3           | BM, walker| 7          | Normal in skin, cultured fibroblasts, and mildly reduced in skeletal muscle | No mutations in COL6A1, COL6A2, COL6A3 |
| 4           | BM, walker| 17         | Normal in skin, cultured fibroblasts, and skeletal muscle | COL6A2: heterozygous Gly7005Ser |
| 5           | UCMD, non-walker| 6       | Marked reduction in cultured skin fibroblasts and in muscle fibers | COL6A2: compound heterozygous Gly487Ala/Glu959delAsp, Gly134X48 |

JOURNAL OF CELLULAR PHYSIOLOGY
Scanning electron microscopy back-scattered imaging
Cu–Pb staining solution was prepared by mixing 20 ml of 4.6% trisodium citrate, 2 ml of 33% lead nitrate, and 0.5 ml of 10% copper sulfate (pH 9), as previously described (LeFurgey et al., 1983), and used undiluted. Cells were fixed with 2.5% glutaraldehyde–0.1 M cacodylate buffer pH 7.3 for 1 h at 4°C. After washing with 0.1 M cacodylate buffer pH 7.3, the coverslips were brought to room temperature, washed three times with distilled water and incubated with Cu–Pb solution at 4°C overnight. The samples were then brought to room temperature, washed three times with distilled water and post-fixed with 1% osmium tetroxide in 0.1 M cacodylate buffer for 1 h at room temperature. After rinsing with 0.1 M cacodylate buffer and then with distilled water, the samples were dehydrated in an ethanol series and critical point dried. The coverslips carrying cells were then mounted on aluminum stubs with silver adhesive paint, coated with spectographic carbon by vacuum evaporation in an Edwards E 306 apparatus, and observed at 0° tilt angle with a Cambridge Stereoscan 200 scanning electron microscope equipped with an Oxford Tetra solid state BSE detector. Acceleration voltage was set at 30 kV and WD at 15 mm.

TUNEL and immunofluorescence analysis
TUNEL assays were performed with the Dead End Fluorometric in situ apoptosis detection system (Promega Italia, Milan, Italy). Muscles cultures were permeabilized in methanol-acetone 50:50 at −20°C for 10 min. After drying, slides were washed in PBS and processed for immunofluorescence with an antibody against desmin (D1033, Sigma). Samples were washed and then incubated with equilibration buffer for 10 min and treated with buffer containing fluorescent nucleotides, rTdT enzyme, and Hoechst 33258 (Sigma) for 1 h at 37°C. SSC solution was used to block the activity of rTdT enzyme, before washing and preparing slides for microscopy analysis.

Results
We tested the effects of oligomycin on the accumulation of TMRM by mitochondria in cell cultures established from muscle biopsies of one UCMD patient and of four patients affected by BM (Table 1). Among these last cases, while one of them has been included in a study previously reported (Angelin et al., 2008), three are new cases, two of which having mutations in one of the COL6 gene, and one with no mutations in none of the COL6 genes. In BM patients 1, 2, and 4, ColVI expression was normal in both muscle fibers and in cultured skin fibroblasts, while in BM patient 3 a mild reduction was detected only in muscle biopsy. In UCMD patient, a marked ColVI reduction was detected in both muscle biopsy and fibroblast culture.

Cell cultures derived from muscle biopsies are heterogeneous, and may contain variable proportions of myoblasts and interstitial fibroblasts. Therefore, we analyzed the relative percentage of desmin-positive cells at different passages of primary cell cultures derived from muscle biopsies of a normal donor, a UCMD patient, and two BM patients (Table 2). A significant, progressive decrease of desmin-positive cells occurs in control as well as in the patient samples, although the initial percentage of myoblasts is highly variable in the patient samples with respect to control. In fact, at passage five, the percentage of myoblasts is highly reduced in all cases. A further significant reduction is detected at passage 12 except for the UCMD patient in which the value was not significantly further decreased.

These data indicate that the cells populations present in a muscle biopsy are differently represented, depending on the disease progression. Furthermore, the percentage of myoblasts is progressively reduced by maintaining cells in culture conditions and by increasing the number of passages. In any case, the main population is constituted by stromal fibroblasts, which substantially represent the bulk of cells at high passages cultures.

In keeping with our previous results on one such patient (Angelin et al., 2007), in all cases the probe was released from mitochondria (Fig. 1), consistent with the existence of a latent mitochondrial dysfunction that can be precipitated by inhibition of the F1F0 ATP synthase, possibly a result of Ca2+ deregulation (Angelin et al., 2008). Since skin fibroblasts from ColVI myopathic patients were reported not to respond with depolarization to oligomycin (Hicks et al., 2009), we investigated whether mitochondrial dysfunction is restricted to myogenic cells.

Primary muscle cultures from a muscle biopsy of a BM patient were grown on grided coverslips, so that the position of individual cells could be tracked, and subjected to treatment with oligomycin, which caused the expected depolarization in a randomly selected group of cells (Fig. 2A). Cells were then fixed, treated with DAPI, and the cells previously monitored for TMRM fluorescence identified (boxed area in Fig. 2B,C). Immunostaining for desmin revealed that only rare cells were positive for this myogenic marker (one in the area shown in Fig. 2C, arrow). On the other hand, all oligomycin-responsive cells were desmin-negative, a result that was fully confirmed in a similar experiment carried out in cultures from the UCMD patient (Fig. 3).

These results indicate that muscle fibroblasts from BM and UCMD patients have a latent mitochondrial dysfunction that can be triggered by oligomycin (Merlini et al., 2008a). Importantly, desmin-negative cells also displayed apoptotic nuclei as detected by the TUNEL reaction (Fig. 4), indicating that the dire consequences of mitochondrial dysfunction are not limited to myogenic cells.

Mitochondrial dysfunction, often caused by opening of the PTP, is causally involved in cell death (Bernardi et al., 2006). We reasoned that in vitro passage of cultures might be selecting cells that are more resistant to death. We therefore tested cultures from one BM and one UCMD patient for their mitochondrial response to oligomycin as a function of the number of passages. For both cell cultures the expected depolarizing response to oligomycin was consistently observed up to the 7th passage, while it disappeared at higher passage numbers, a result that we have confirmed with all the cell cultures of the present study although the full time-course was performed only for the two cases shown in Figure 5.

A statistical analysis was performed by pooling the results obtained from measurements performed on cells passages up to seven times, or more than nine. The difference was striking and highly significant (Fig. 6A,B). We tested if a similar resistance could be observed in response to rotenone, which also causes depolarization of mitochondria in cells from UCMD patients presumably because of the altered voltage threshold of the PTP (Angelin et al., 2008). Also in the case of treatment with rotenone depolarization was observed with early- but not late-passage cultures from both the BM (Fig. 6A) and the UCMD patient (Fig. 6B). The striking selection of depolarization-resistant cells was matched by an abrupt decrease of the incidence of apoptotic nuclei after 11 passages.

| Cell culture | Passage 0 | Passage 5 | Passage 12 |
|--------------|-----------|-----------|------------|
| Control      | 37.0 ± 3.6| 7.0 ± 2.6  | 1.2 ± 0.7  |
| Patient 1    | 25.0 ± 2.6| 0.7 ± 0.5  | 0.2 ± 0.1  |
| Patient 2    | 12.0 ± 3.0| 3.0 ± 0.9  | 1.9 ± 0.6  |
| Patient 5    | 29.6 ± 2.2| 5.8 ± 1.6  | 5.5 ± 1.3  |

*Significance calculated by Mann-Whitney test P < 0.01.
Fig. 7), a result that is reminiscent of that obtained by plating cells from ColVI myopathy patients on ColVI, or by treating them with CsA (Angelin et al., 2007).

We finally investigated whether the resistant cells also had a lower incidence of mitochondrial ultrastructural abnormalities, which are characteristic of the mouse Colba1−/− model (Irwin et al., 2003) and can also be observed in cultures established from muscle biopsies of UCMD and BM patients (Angelin et al., 2007). Back scattered imaging of cultured cells allowed to clearly monitor both organization and extension of the mitochondrial reticulum by exploiting the specific staining of mitochondrial membranes with copper-lead salts solutions (Thiéry, 1973). At low passage number, both UCMD (patient 5) and BM (patient 2) cells showed reduced mitochondrial branching, and some fragmented and swollen mitochondria were detected. At high passage numbers, the mitochondrial reticulum appeared more developed and similar to controls as...
long, thin and branched mitochondria were detected (Fig. 8). Mitochondrial abnormalities were also detected in thin sections of UCMD and BM patient cells when examined at low passage number. The most relevant alterations consisted in an increased mitochondrial area/perimeter ratio (72% in UCMD and 41% in BM muscle cell cultures, higher than those of an unaffected donor with \( P < 0.05 \)) and reduced short axis (between 90 and 120 nm in BM and UCMD patients, and >200 nm in unaffected donor). Rare swollen mitochondria as well as megacomial aspects were also detected in cultures of

---

**Fig. 4.** Occurrence of apoptosis in cells from the muscle biopsy of the UCMD patient. Representative image of the immunohistochemical analysis performed on early-passage cell cultures (less than seven passages) established from muscle biopsies of the UCMD patient treated with an antibody against desmin (red) and counterstained with Hoechst (part A) and subjected to the TUNEL reaction (part B, two positive nuclei marked by arrows).

---

**Fig. 5.** Analysis of the mitochondrial response to oligomycin in cells derived from one BM and one UCMD patient after different passages in culture. Cultures established from muscle biopsies of one patient with BM and one patient with UCMD were tested for the mitochondrial response to oligomycin after the indicated number of culture. Where indicated 6 \( \mu \text{M} \) oligomycin (O) and 4 \( \mu \text{M} \) FCCP (F) were added. Each trace represents the mean \( \pm \) SEM of at least three experiments.
both patients. Remarkably, the area/perimeter ratio and short axis values at passage 12 were instead similar to those of unaffected donor at the same passage number (Fig. 9).

Discussion

Interstitial fibroblasts from muscle biopsies could represent a resource for diagnostic tests in UCMD and BM patients, because these cells have been reported to be the main source of ColVI in skeletal muscle (Zou et al., 2008). It is therefore important to assess whether the mitochondrial membrane potential and its response to oligomycin and rotenone can be used as a suitable index of mitochondrial latent dysfunction in cell cultures obtained from patient muscular biopsies.

Given the heterogeneity of cell cultures derived from muscle biopsies, the principal aim of this study was to determine to which extent, they can be utilized to determine mitochondrial dysfunction in ColVI-related myopathies.

In previous studies, a latent mitochondrial dysfunction that can be unmasked by the addition of oligomycin has been measured based on the response of mitochondrial TMRM in the Col6−/− mouse model (Irwin et al., 2003). The mitochondrial defect could also be observed in isolated myofibers freshly prepared from muscle biopsies of Col6−/− mice and in muscle cultures of UCMD patients; the mitochondrial defect and increased rate of apoptosis could be rescued by plating cells on purified ColVI or by treatment with CsA (Irwin et al., 2003; Angelin et al., 2007). Similar results have been obtained in a clinical study on five patients, in which cells derived from a muscular biopsy before and after 20 day treatment with CsA have been studied (Merlini et al., 2008a). In these conditions, the primary cell cultures contained 25–35% desmin-positive cells, while the majority of the other desmin-negative, vimentin-positive cells, conceivably represent interstitial muscle fibroblasts (Bernardi et al., 2009). It is well known that maintenance in culture of muscle-derived cells progressively causes a reduction of myoblasts, so that after 5–7 passages, the percentage of desmin-positive cells is highly reduced, possibly due to the higher proliferation rate of fibroblasts. On the other hand, fibroblasts in muscle are a key mechanistic component in ColVI-related myopathies, because interstitial fibroblasts play a role in prepatterning muscle development (Kardon et al., 2003) and are involved in the synthesis and arrangement of the ECM and of ColVI in muscle (Engvall et al., 1986; Zou et al., 2008). Interestingly, the retention of ColVI in interstitial fibroblasts but not in myocytes in biopsies of patients with known ColVI-retaining mutations, point to fibroblasts as the cells to be analyzed in the culture systems (Zou et al., 2008).

Mutant ColVI is retained in dermal fibroblasts from a UCMD patient (Pan et al., 2003) and in dermal fibroblasts in culture obtained from BM and UCMD patients (Zou et al., 2008). Therefore, it has been inferred that skin biopsy-derived fibroblasts should be utilized for diagnostic use in ColVI-related myopathies (Hicks et al., 2008).
In a recent study of mitochondrial dysfunction and its rescue, PTP dysregulation has been analyzed by utilizing skin fibroblasts from biopsies of a group of patients and muscle-derived cell cultures obtained from a Tissue Culture Collection (Hicks et al., 2008). A result of this study indicated that mitochondrial depolarization inducible by oligomycin is not common in skin biopsy-derived fibroblasts cells of BM and UCMD patients, being present only in a case showing a complete absence of intracellular and extracellular ColVI (Hicks et al., 2008). This finding suggests that skin fibroblasts may not display mitochondrial dysfunction, which is instead present in their muscle-derived, desmin-negative muscle fibroblasts, suggesting that great care should be exerted in utilizing these samples to monitor mitochondrial dysfunction. A further result of the same investigation indicated that mitochondrial depolarization was present in UCMD muscle-derived cell cultures but not in fibroblast cultures from the same patient (Hicks et al., 2008). The interpretation of this result deserves a critical analysis, because whether or not a mitochondrial phenotype can be detected in cells from a patient biopsy is an important issue for inclusion in clinical trials. In this study we have addressed this problem experimentally.

Our results show that latent mitochondrial dysfunction is present both in muscle cells and in muscle fibroblasts derived from muscle cultures of UCMD and BM patients. These results confirm that mitochondrial dysfunction is a key feature of ColVI-related diseases. Moreover, the persistence of a mitochondrial dysfunction in cell cultures derived from myopathic patients may have a key diagnostic significance.

The mitochondrial dysfunction has been documented in three BM patients, not included in our previous studies; interestingly, two of these patients present mutations in one of the ColVI chains, while one patient does not present ColVI-related mutations. However, in this patients, whose genetic profile is under investigation, ColVI expression appears to be reduced, possibly owing to a secondary effect of a not yet identified genetic defect.

This suggests that the pathogenic mechanism leading to mitochondrial dysfunction could be effective also in other myopathies; this possibility has been recently confirmed in a study where oligomycin-induced mitochondrial depolarization has been observed also in cells derived from a patient affected by limb-girdle muscular dystrophy 2B (Hicks et al., 2009).

Our current findings confirm the importance of mitochondria in the pathogenesis of ColVI muscular dystrophies and their role as potential targets for therapy (Angelin et al., 2007). Additional evidence for the mitochondrial pathogenesis of ColVI muscular dystrophies came from recent work in zebrafish, an organism where the PTP has regulatory features indistinguishable from those of mammals (Azzolin et al., 2010). Injection of morpholino to exon 13 of col6a1 caused an in-frame deletion in the C-terminal part of the ColVI triple helical domain, a typical dominant BM mutation (Lucioli et al., 2005; Lampe et al., 2008) and resulted in a mild myopathy with late-onset motor deficits and obvious histopathologic abnormalities (Telfer et al., 2010). Injection of morpholino to exon 9 of col6a1 caused an in-frame deletion in the N-terminal part of the triple helical domain, a dominant mutation in UCMD (Pepe et al., 2006; Lampe et al., 2008) and resulted in the predicted severe myopathy with early-onset motor deficits and severe ultrastructural changes (Telfer et al., 2010). In both cases mitochondrial abnormalities and increased
apoptosis were observed, and treatment with CsA improved these pathological signs together with the motor deficit (Telfer et al., 2010).

Here we reported that the mitochondrial dysfunction detectable in cultured cells from ColVI-related myopathies is conserved in cultures at low passage number. On the other hand, in cell cultures at high passage number mitochondrial function appeared to be normalized, as assessed on the lack of depolarization by both oligomycin and rotenone and on recovery of a normal morphology by both transmission and scanning electron microscopy with back-scattered imaging. Remarkably, apoptotic levels also dropped dramatically, supporting a cause–effect relationship between mitochondrial function and cell survival.

It is well known that cell cultures obtained from muscle biopsies are heterogeneous, including myoblasts, muscular fibroblasts, myofibroblasts, and rare mesenchimal stem cells; all these cells may undergo selection/modification processes during passage in culture.

Since the relative amount of the two cell populations changes along the observed period of culture, the selection of a cell population seems to occur. The percentage of desmin-positive cells, in fact, decreases relative to that of desmin-negative cells in late passages, probably because muscular fibroblasts proliferate at a higher rate compared to myoblasts.

It is well known that cells from ColVI deficient mice and UCMD/BM patients present a “latent” mitochondrial dysfunction, which can be unmasked by oligomycin. It is thus quite possible that, in cell culture condition, cells having only a dysfunction, which can be unmasked by oligomycin. It is thus quite possible that, in cell culture condition, cells having only a dysfunction, which can be unmasked by oligomycin. It is thus possible that, in cell culture condition, cells having only a reduced percentage of damaged mitochondria may survive, so that, after a given number of passages, the triggering effect of oligomycin on latent mitochondrial depolarization is lost.

In conclusion, our data indicate that the mitochondrial response to oligomycin and rotenone can be used as a criterion for inclusion in clinical trials and as an outcome measure of the patient response to therapy (Merlini and Bernardi, 2008; Merlini et al., 2008a). However, the observed decrease of response to these drugs suggests that cells obtained from muscle biopsies can be utilized at low-passages only, because the permanence in cell culture appears to select resistant cell populations through mechanisms that require further investigation.

Acknowledgments

This work was supported by Italian University Ministry grant PRIN 2008PB5S89, by Telethon Italy grant GGP11082 and by “Fondazione Carisbo”.

Literature Cited

Angelin A, Tiepola T, Sabatelli P, Grumati P, Bergamin N, Gualandi F, Bertini E, merlini L, Maraldi NM, Bernardi P, Maraldi BM. 2008. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Natl Acad Sci USA 104:991–996.

Angelin A, Bonaldo P, Bernardi P. 2008. Altered threshold of the mitochondrial permeability transition pore in Ullrich congenital muscular dystrophy. Biochim Biophys Acta 1777:893–896.

Azziolin L, Basso E, Argenton F, Bernardi P. 2010. Mitochondrial Ca2+ transport and permeability transition in zebrafish (Danio rerio). Biochim Biophys Acta 1797:1725–1739.

Bergamin N, Krauskopf A, Basso E, Petronilli V, Blachly-Dyson E, Di Lisa Forte MA. 2006. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J 273:2077–2099.

Bernardi P, Bonaldo P, Maraldi BM, Merlini L, Sabatelli P. 2009. On the pathogenesis of collagen VI muscular dystrophies—Comment on article of Hicks et al. Brain 132:1121.

Bottemil J, Wingarden GK. 1976. Benign myopathy, with autosomal-dominant inheritance. A report on three pedigrees. Brain 99:91–100.

Camacho Vanegas O, Bertini E, Zhang RZ, Petronilli S, Minossi C, Sabatelli P, Giusti B, Mihm P. 2006. Ullrich scleroreticulocytic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci USA 98:7516–7521.

Dennen E, Sabatelli P, Alwishah S, Varesaso F, Moghadamzadeh B, Mairelaud M, Topaegis H, Cuenne B, Merlino L, Guicciardi P. 2002. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet 70:1446–1458.

Engvall E. Hesle H, Kiler G. 1986. Molecular assembly, secretion, and matrix deposition of type VI collagen. J Cell Biol 102:703–710.

Grumati P, Coletta L, Sabatelli P, Cescon M, Angelin A, Blauw B, Bertaggi E, Uricolo A, Tiepolo T, Merlino L, Maraldi NM, Bernardi P, Sandri M, Bonaldo P. 2010. Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myopathic degeneration. Nat Med 16:1313–1320.

Hicks D, Lampe AK, Barresi R, Charlebois R, Fiorelli C, Bonnefond C, Hudson J, Sutton R, Lochmuller H, Straub V, Busby K. 2008. A refined diagnostic algorithm for Bethlem myopathy. Neurology 70:1192–1199.

Hicks D, Lampe AK, Lavel SH, Alward BM. Angelin A, Bonaldo P, Bernardi P, Maraldi NM, Bernardi P, Maraldi BM. 2008. Mitochondrial dysfunction in cultured cells from patients with Bethlem myopathy. Neurology 70:1446–1458.

Irwin WA, Bergamin N, Sabatelli P, Reggiani C, Meeghan A, Merlino L, Braghetta P, Columbaro M, Volpin D, Bressan QM, Bernardi P, Bonaldo P. 2003. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 35:267–271.

Iyengar P, Combis TP, Shah SJ, Gouwen-Er vans V, Pollard JW, Alsaleem N, Flanagan L, Turemwood MP, Gaha C, Lison MP, Paulet RG, Scherer PE. 2003. Adipocyte-secreted factors synergistically promote mammalian tumorigenesis through induction of antipotopic transcriptional programs and pro-angiogenic stabilization. Oncogene 22:6408–6423.

Jobissi GJ, Boers JM, Barth PG, de Visser M. 1999. Bethlem myopathy: A slowly progressive congenital muscular dystrophy with contractions. Brain 122:649–655.

Kadon G, Harfe BD, Tabin CJ. 2003. A TGF-positive mesodermal population provides a prepattern for vertebral limb muscle patterning. Dev Cell 3:973–944.

Keene DR, Engvall E, Glamville RW. 1988. Ultrastructure of type VI collagen in human skin and cartilage suggests an anchoring function for this filamentous network. J Cell Biol 107:1995–2006.

Kishin PC, Soriano ME, Irwin W, Parada D, Scarrsana L, Bathe A, Neumann HG, Bernardi P. 2003. Early resistance to cell death and to onset of the mitochondrial permeability transition during hepatocarcinogenesis with 2-acetylaminofluorene. Proc Natl Acad Sci USA 100:10014–10019.

Kuo HJ, Macln SL, Keene DR, Glamville RW. 1997. Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Bio Chem 272:26252–26259.

Lampe AK, Bushby K. 2005. Collagen VI-related muscle disorders. J Med Genet 42:1725–1729.

Lampe AK, Zou Y, Souda N, Uberi KK, Hicks D, Lavel SH, Charlton R, Jmenez-Mallebrera C, Zhang RZ, Finkel JS, Tiennoo K, Schreiber G, van der Knaap MS, Marks H, Strabu V, Flanagan KM, Chu ML, Munoz-Montes F, Bushby K, Bernardi P. 2008. Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Hum Mutat 29:809–822.

Lafruge A, Ingram P, Henry SC, Murphy E, Lieberman M. 1983. Three-dimensional configuration of the mitochondria in cultured heart cells. Scan Electron Microsc 1:293–303.

Luciti S, Giusti B, Mercuri E, Yanagas OC, Lucaris L, Piroozin V, Urzibizara A, Ben Yaou R, de Visser M, van der Kool AJ, Bonnefond I, Imanne LM, Merlini L, Bushby K, Muntoni F, Bertini E, Chu ML, Pepe G. 2005. Detection of common and private mutations in the COL6A1 gene in patients with Bethlem myopathy. Neurology 64:1931–1937.

Merlini L, Bernardi P. 2008. Therapy of collagen VI-related myopathies (Bethlem and Ullrich). Neurotherapeutics 5:613–618.

Neuromuscul Disord 42:6408–6423.
Merlini L, Angelin A, Tiepolo T, Braghetta P, Sabatelli P, Zamparelli A, Ferlini A, Maraldi NM, Bonaldo P, Bernardi P. 2008a. Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci USA 105:5225–5229.

Merlini L, Martoni E, Grumati P, Sabatelli P, Squarzoni S, Urciuolo A, Ferlini A, Gualandi F, Bonaldo P. 2008b. Autosomal recessive myosclerosis myopathy is a collagen VI disorder. Neurology 71:1245–1253.

Palma E, Tiepolo T, Angelin A, Sabatelli P, Maraldi NM, Basso E, Forte MA, Bernardi P, Bonaldo P. 2009. Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice. Hum Mol Genet 18:2024–2031.

Pan TG, Zhang RZ, Sudano DG, Marie SK, Bonnemann CG, Chu ML. 2003. New molecular mechanism for Ullrich congenital muscular dystrophy: A heterogeneous in-frame deletion of COL6A1 gene causes a severe phenotype. Am J Hum Genet 73:355–369.

Pepe G, Bertini E, Bonaldo P, Bushby K, Giusti B, de Visser M, Guicheney P, Lattanzi G, Merlini L, Muntoni F, Nishino I, de Visser M, Yang RB, Sabatelli P, Sewry C, Topaloglu H, van der Kooi A. 2002. Bethlem myopathy (Bethlem) and Ullrich scleratonic muscular dystrophy: 100th ENMC international workshop, 23–24 November 2001, Naarden, The Netherlands. Neumuscul Oxid 12:984–993.

Pepe G, Lucarini L, Zhang RZ, Pan TC, Giusti B, Quijano-Roy S, Gartioux C, Bushby KM, Guicheney P, Chu ML. 2006. COL6A1 genomic deletions in Bethlem myopathy and Ullrich muscular dystrophy. Ann Neural 59:190–195.

Schessl J, Zou Y, Bonnemann CG. 2006. Congenital muscular dystrophies and the extracellular matrix. Semin Pediatr Neurol 13:80–89.

Sherman-Baust CA, Weisgraber AT, Rangel LB, Przar ES, Cho KR, Schwartz DR, Shock T, Morin PJ. 2003. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3:377–386.

Squarzoni S, Sabatelli P, Bergamin N, Guicheney P, Demir E, Merlini L, Lattanzi G, Ognibene A, Capanni C, Mattioli E, Columbaro M, Bonaldo P, Maraldi NM. 2006. Ultrastructural defects of collagen VI filaments in an Ullrich syndrome patient with loss of the alpha3(VI) N10–N7 domains. J Cell Physiol 206:160–166.

Telfer WR, Busta AS, Bonnemann CG, Feldman EL, Dowling JJ. 2010. Zebrafish models of collagen VI-related myopathies. Hum Mol Genet 19:2433–2444.

Thiéry G. 1973. Colorations permettant l’étude des coupes épaisse, leur intérêt en microscopie électronique. J Microsc 17:101–104.

Tiepolo T, Angelin A, Palma E, Sabatelli P, Merlini L, Nicolosi L, Finetti F, Braghetta P, Vuigniaux G, Dumont JM, Baldani CT, Bonaldo P, Bernardi P. 2009. The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1−/− myopathic mice. Br J Pharmacol 157:1045–1052.

Zhang RZ, Sabatelli P, Pan TC, Squarzoni S, Mattioli E, Bertini E, Pepe G, Chu ML. 2002. Effects on collagen VI mRNA stability and microfibrilar assembly of three COL6A2 mutations in two families with Ullrich congenital muscular dystrophy. Br J Pharmacol 137:1555–1564.

Zou Y, Zhang RZ, Sabatelli P, Chu ML, Bonnemann CG. 2008. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: Implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neural 67:144–154.